27 September 2019 - New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that significantly reduced the risk of disease progression by 38% compared with chemotherapy (nab-paclitaxel) alone.

Roche Canada announced today that Health Canada under the Notice of Compliance with Conditions (NOC/c) policy has approved Tecentriq (atezolizumab) in combination with chemotherapy (nab-paclitaxel) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1%, and who have not received prior chemotherapy for metastatic disease. Tecentriq is the first and only approved cancer immunotherapy agent in Canada for first-line TNBC. This approval meets a significant unmet need for TNBC patients.

This approval is based on results from the randomized Phase III IMpassion130 study.

Read Roche press release